PKM2 Inhibitor (Compound 3k): Selective Glycolytic Modulation in Cancer and Immunometabolism

Executive Summary: PKM2 inhibitor (compound 3k) is a validated, selective pyruvate kinase M2 inhibitor with an IC50 of 2.95 μM, exhibiting potent antiproliferative activity in multiple cancer models according to product data. In vivo, oral dosing at 5 mg/kg every two days for 31 days significantly reduces tumor volume in SK-OV-3 xenografted BALB/c nude mice without major organ toxicity. Recent studies reveal that PKM2 inhibition also modulates immune cell metabolism—particularly macrophage polarization—by interfering with glycolytic reprogramming, as shown in severe acute pancreatitis models (Wu et al., 2025). Compound 3k’s selective cytotoxicity for tumor cells over normal cells highlights its potential for targeted metabolic therapy. This article details the biological rationale, mechanism, benchmarks, and workflow guidance supported by primary literature and authoritative product specifications.

Biological Rationale

Pyruvate kinase M2 (PKM2) is a critical enzyme in the glycolytic pathway, catalyzing the conversion of phosphoenolpyruvate (PEP) to pyruvate. PKM2 is predominantly expressed in tumor cells and activated immune cells, where it supports the metabolic demands of rapid proliferation and inflammation. Its overexpression is associated with aerobic glycolysis (the Warburg effect), a metabolic hallmark of many cancers and inflammatory responses in macrophages (Wu et al., 2025). Inhibiting PKM2 restricts this glycolytic flux, impeding tumor growth and inflammatory polarization. APExBIO's PKM2 inhibitor (compound 3k) was developed to selectively target PKM2, providing a tool for dissecting glycolytic control in cancer and immune-mediated diseases.

Mechanism of Action of PKM2 inhibitor (compound 3k)

Compound 3k is a small molecule with the formula C18H19NO2S2 and molecular weight 345.48. It binds selectively to PKM2, inhibiting its enzymatic activity with an in vitro IC50 of 2.95 μM (APExBIO product documentation). By blocking PKM2, compound 3k disrupts the last step of glycolysis, decreasing pyruvate and ATP generation in highly glycolytic cells. In cancer cells, this results in reduced proliferation and induction of autophagic cell death. In inflammatory macrophages, PKM2 inhibition reduces the glycolytic phenotype, shifting polarization from pro-inflammatory (M1) to anti-inflammatory (M2) states (Wu et al., 2025). These dual effects in oncology and immunometabolism are unique to selective PKM2 inhibitors.

Evidence & Benchmarks

• Compound 3k inhibits PKM2 with an IC50 of 2.95 μM (in vitro), as indicated in the product information.
• Antiproliferative activity in cancer cell lines: HCT116 (IC50 = 0.18 μM), Hela (IC50 = 0.29 μM), and H1299 (IC50 = 1.56 μM); normal cell line BEAS-2B shows higher IC50, indicating selectivity (APExBIO).
• In vivo efficacy: Oral administration at 5 mg/kg every two days for 31 days reduced tumor volume and weight in SK-OV-3 xenografts in BALB/c nude mice without major organ toxicity or significant weight loss (APExBIO).
• In severe acute pancreatitis models, PKM2 inhibition via compound 3k partially reversed the protective effects of USP7 knockdown, confirming PKM2’s role in macrophage metabolic polarization (Wu et al., 2025).
• Compound 3k demonstrates solubility in DMSO at ≥34.5 mg/mL with gentle warming, but is insoluble in ethanol and water (APExBIO).

Compared to prior reviews such as "PKM2 Inhibitor (Compound 3k): Beyond Oncology—Metabolic Modulation and Immune Reprogramming", which focused on the broader immune cell context, this article provides direct protocol parameters and quantitative benchmarks for translational workflows.

For a strategic analysis of translational directions, see "PKM2 Inhibitor (Compound 3k): Strategic Advances in Cancer Metabolism"; this article expands by adding new in vivo and immunometabolic data from recent studies.

Applications, Limits & Misconceptions

PKM2 inhibitor (compound 3k) is validated for use as a cancer cell metabolism inhibitor, with proven efficacy against multiple tumor types in vitro and in vivo. Its selective cytotoxicity profile suggests utility as an antiproliferative agent for cancer cells and as a probe for tumor cell specific PKM2 targeting. In immune research, it serves as a tool for studying metabolic reprogramming and disease modulation, as shown in severe acute pancreatitis models (Wu et al., 2025).

However, compound 3k’s utility outside of PKM2-overexpressing cells or non-glycolytic disease models is not supported by current evidence. In vivo dosing and solubility constraints (DMSO only) may limit certain applications.

Common Pitfalls or Misconceptions

• Compound 3k is not effective in cell types lacking PKM2 overexpression; normal cells generally show reduced sensitivity (APExBIO).
• It should not be used in aqueous or ethanol-based vehicles due to insolubility; DMSO is required for stock solutions.
• The compound is not a pan-pyruvate kinase inhibitor; selectivity is for PKM2 over other isoforms.
• Therapeutic claims in humans are not established; all efficacy data are from preclinical models.
• Prolonged solution storage is not recommended; short-term use only, as per manufacturer instructions.

Workflow Integration & Parameters

Protocol Parameters

• In vitro PKM2 inhibition: Use at concentrations yielding 2.95 μM IC50; titrate from 0.1 to 10 μM for cell-based assays to characterize dose-response (APExBIO).
• Antiproliferative assays: Recommended for cancer cells (HCT116, Hela, H1299) with IC50 range 0.18–1.56 μM; normal cell controls are necessary.
• In vivo dosing: 5 mg/kg oral administration every 2 days for 31 days in BALB/c nude mice with SK-OV-3 xenografts; monitor for weight and organ toxicity.
• Solubility and storage: Prepare at ≥34.5 mg/mL in DMSO with gentle warming; store powder at -20°C and use solutions immediately or within recommended short-term period.
• Immune modulation studies: Use in models of severe acute pancreatitis or macrophage polarization for metabolic reprogramming research (refer to Wu et al., 2025).

Conclusion & Outlook

Compound 3k, a selective PKM2 inhibitor developed by APExBIO, is well-characterized as a disruptor of tumor and immune cell glycolysis, with robust preclinical evidence for antiproliferative and immunometabolic effects. Its dual application in cancer and inflammatory disease models is supported by quantitative data and mechanistic insight. Ongoing research is warranted to clarify its translational potential and address solubility and delivery constraints. For further mechanistic insight on USP7–PKM2 crosstalk, refer to "USP7 Regulates Macrophage Polarization via PKM2 in SAP", which complements this article by focusing on upstream regulatory mechanisms in immune cells.